Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 13.45% · OPTIONAL
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTTenon Medical, Inc.'s latest supported as-filed period reports revenue of $1.3M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 13.45% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -215.64% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 126.77% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 61.22% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 63.64% · CORE
Level · gp.fundamentals.operating_margin
Raw value -262.24% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 78.6%; Operating cash flow decreased 24.6%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 126.8%; Operating margin moved 24432 bp higher; Operating income decreased 17.4%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 126.8%; Operating margin moved 24432 bp higher; Operating income decreased 17.4%.
3 evidence-backed componentsOperating cash flow changed -24.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TNON · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-098774SEC ↗8-KSep 9, 2026Period Sep 9, 20260001213900-26-098232SEC ↗4Sep 8, 2026Period Aug 26, 20260001475597-26-000234SEC ↗4Sep 3, 2026Period Aug 26, 20260001475597-26-000230SEC ↗4Sep 1, 2026Period Aug 26, 20260001475597-26-000226SEC ↗8-KAug 31, 2026Period Aug 27, 20260001213900-26-095686SEC ↗4Aug 31, 2026Period Aug 26, 20260001475597-26-000221SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 9, 2026Filed Sep 10, 2026 | Williamson KevinChief Financial Officer | Tax WithholdingDirect | 11 | $3 | $38 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Williamson KevinChief Financial Officer | Option ExerciseDirect | 30 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Williamson KevinChief Financial Officer | Option ExerciseDirect | 30 | $0 | $0 | Form 4 ↗ |
| Sep 4, 2026Filed Sep 8, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 1,506 | $4 | $5,572 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 8, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 60.05% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 32.21% · OPTIONAL
Trade receivables changed +152.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -10113 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -46.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current liabilities changed +224.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed +24432 basis points from the comparable as-filed period.
Research & development changed +52.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-093926| HRT FINANCIAL LPReporting owner |
| Open Market PurchaseDirect |
| 1,658 |
| $4 |
| $6,599 |
| Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 450 | $5 | $2,039 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | HRT FINANCIAL LPReporting owner | Open Market PurchaseDirect | 1,790 | $5 | $8,180 | Form 4 ↗ |
| Aug 31, 2026Filed Sep 1, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 1,276 | $5 | $5,946 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | HRT FINANCIAL LPReporting owner | Open Market PurchaseDirect | 12,376 | $5 | $64,479 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | HRT FINANCIAL LPReporting owner | Open Market PurchaseDirect | 5,981 | $6 | $37,979 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 4,932 | $7 | $34,869 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 2,091 | $8 | $16,519 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 31, 2026 | HRT FINANCIAL LPReporting owner | Open Market SaleDirect | 419 | $5 | $2,078 | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | WEIGLE ROBERT KDirector | Option ExerciseDirect | 10,732 | $0 | $0 | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | WEIGLE ROBERT KDirector | Option ExerciseDirect | 10,732 | $0 | $0 | Form 4 ↗ |